DuPont Shorts Retreat While Analysts Trim Targets

DuPont de Nemours enters its November 3 earnings release with short sellers pulling back sharply, even as the analyst community has been quietly marking down its price targets across the board.

Short interest in DuPont is modest by any measure, at roughly 1% of the free float, and it has been falling fast. Positions dropped 15% over the past week to around 4.25 million shares, unwinding a brief spike that peaked near 5.2 million in mid-October. Among the closest peers, 3M carries meaningfully more short exposure in absolute terms, and Siemens has attracted noticeably more borrow demand relative to its float. DuPont is the least crowded trade in this peer group. The borrow market reflects that: availability is exceptionally loose at over 5,500%, meaning there are far more shares available to lend than are currently borrowed, and cost to borrow sits near 0.49%, barely above its recent range. Shares have added 7.6% over the past month and 2.6% over the past week, lagging only slightly behind the median peer gain of 3.2%.

Options positioning is equally relaxed. The put/call ratio of 0.33 is only marginally above its 20-day average and well within its normal range, suggesting no particular demand for downside protection ahead of the release. The picture across lending, positioning, and recent price action is consistently calm: this is not a stock with an aggressive short thesis in place.

The sharper tension is in the analyst debate. Several major firms cut their price targets in October, with JP Morgan going further and downgrading the stock to Neutral from Overweight while trimming its target to $145, close to where the stock is currently trading. RBC Capital and Citi also lowered their targets, though both maintained positive ratings. Barclays initiated coverage at Overweight with a $156 target. The mean target across the group sits at around $165, implying roughly 18% upside from the current price of $140, but the direction of travel has been downward. The constructive case rests on Healthcare and Water Technologies delivering continued mid-single-digit organic growth, free cash flow conversion above 100%, and management's plan for more than $500 million in buybacks during 2026. The more cautious view points to electronics and construction weakness, a slow China recovery, and the risk that synergies from recent portfolio moves take longer to materialise than the current valuation assumes.

Wikipedia page traffic for DuPont is running more than two standard deviations above its own 90-day average, a notable uptick in retail attention in the days before the print. The dataset has no measured relationship to the company's reported financials, so it speaks to investor interest rather than business momentum, but the timing is worth noting.

The November 3 print is therefore a test of whether DuPont's Healthcare and Water segments can sustain their growth rates convincingly enough to pull analyst targets back higher, or whether the recent wave of target cuts reflects a more durable reassessment of the earnings trajectory.